Top Tweets for #ACSCancerchat
What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan #ACSCancerChat
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 @apolo_andrea @PGrivasMDPhD @shilpaonc @neerajaiims @DrChoueiri @TiansterZhang @amerseburger @nataliagandur @Martin_AngelMD @DrYukselUrun EV SG and DV all going fast. We’re expecting EV and Pembro R3 results in the 1st line and MIBC space in the not too distant future . SG vs chemo in platinum refractory disease is v. exciting. I’d like to see combos of these agents @DrChoueiri DV phase II data also #ACScancerchat
On behalf of @OncoAlert 🚨
Thank you #ACSCancerChat and our friends at @JournalCancer !!!
Amazing conversations @drfrankiejs @tompowles1 , Dr. Matthew Young, @VivekSubbiah
@WalterStadler5
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 @apolo_andrea @PGrivasMDPhD @shilpaonc @neerajaiims @DrChoueiri @TiansterZhang @amerseburger @nataliagandur @Martin_AngelMD @DrYukselUrun EV SG and DV all going fast. We’re expecting EV and Pembro R3 results in the 1st line and MIBC space in the not too distant future . SG vs chemo in platinum refractory disease is v. exciting. I’d like to see combos of these agents @DrChoueiri DV phase II data also #ACScancerchat
Last #ACSCancerChat question @drfrankiejs @tompowles1 & Dr. Young 🙏
What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan❓
@OncoAlert 🚨 @VivekSubbiah @WalterStadler5
@JournalCancer @QMBCI @tompowles1 @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur mCSPC what is the role of triplet therapy? (ADT + Docetaxel + ARAT) #ACSChemochat
Looks like our hour is drawing to a close. Any last-minute thoughts from our panelists or members of our audience? #ACSCancerChat
Is there a role for discontinuing immunotherapy in patients with an excellent response, if so when? #ACSCancerChat @tompowles1 @drfrankiejs
What advancements have been made in tx of metastatic castrate-sensitive #ProstateCancer ✅Specially regarding3⃣triplet therapy
@OncoAlert 🚨 #ACSCancerChat
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 I think pateint selection here is going to be really important - also HSPC PARP studies and the new androgen degraders are super exciting.
@VivekSubbiah @JournalCancer @QMBCI @tompowles1 @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur The results of the work on nectin4 has not been consistent. The result relies on a H score (based on IHC). Because majority of bladder ca express nectin4 to some degree, it’s not been a major focus. A recent publication from Germany suggests more work is required #ACScancerchat
@tompowles1 @JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur @NEJM Interesting study was also published in @TheLancetOncol Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study @DrChoueiri #ACSCancerChat https://t.co/ZKEw0O5GqX
@tompowles1 @JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur Here is the paper on Belzutifan "Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease" @NEJM @JournalCancer #ACScancerchat
https://t.co/TNXnHmojSG
@JournalCancer @tompowles1 Dr Matthew Young @BartsECMC “EV302: 1L EV and pembro. The most recent chemotherapy and nivolumab trial warrants close attention. Also looking forward to data from new Antibody drug conjugates in bladder ca (RC-48 trialling Disitimab Vedotin - phase II ongoing) #ACScancerchat”
What are current challenges & limitations in the use of immune checkpoint inhibitors🧪 in the adjuvant setting for renal cell carcinoma #KidneyCancer ?
#ACScancerchat @OncoAlert 🚨
@weoncologists @tompowles1 @OncoAlert @VivekSubbiah @WalterStadler5 Challenges are 1)not selecting patients 2)risk of 10% life changing toxicity and 3) no overall survival benefit yet. Patients need to be aware of these limitations #ACScancerchat
I'll put my bet on "yes" but just barely since everolimus is not much better than a toxic placebo. #ACSCancerChat
@JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur HIF2a is an important new target In RCC. Belzutifan looks really good in VHL driven disease and looks like a great combination partner. Most exciting R3 in the near future in RCC is belzutifan vs everolimus IMO. Do you think it will be possible for OS? #ACScancerchat
Quick #ACSCancerChat question
@drfrankiejs @tompowles1 & Dr. Young
What advancements have been made in tx of metastatic castrate-sensitive #ProstateCancer
✅Specially regarding3⃣triplet therapy🧪& tx of high-risk nonmetastatic disease
@OncoAlert @VivekSubbiah @WalterStadler5
@JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur HIF2a is an important new target In RCC. Belzutifan looks really good in VHL driven disease and looks like a great combination partner. Most exciting R3 in the near future in RCC is belzutifan vs everolimus IMO. Do you think it will be possible for OS? #ACScancerchat
@weoncologists @tompowles1 @OncoAlert @VivekSubbiah @WalterStadler5 Challenges are 1)not selecting patients 2)risk of 10% life changing toxicity and 3) no overall survival benefit yet. Patients need to be aware of these limitations #ACScancerchat
@JournalCancer @tompowles1 The introduction of adjuvant therapy in renal cancer, triplet therapy in prostate cancer and EV/Pembro combination in bladder cancer. These have all had a major impact on practice. #ACSCancerchat
Quick #ACSCancerChat question to @drfrankiejs,
@tompowles1, and Dr. Matthew Young.
What are current challenges & limitations in the use of immune checkpoint inhibitors🧪 in the adjuvant setting for renal cell carcinoma #KidneyCancer ?
@OncoAlert 🚨 @VivekSubbiah @WalterStadler5
.@drfrankiejs @tompowles1: In your expert opinion, which advance would you consider to be the biggest development in genitourinary cancer treatment? #ACSCancerChat
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.6M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.2M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.5M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69.1M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.8M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.3M followers